Skip to main content

Cytokine Induced Memory-like Natural Killer Cells

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

  • RegistryNCT06138587
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia
  • SponsorDana-Farber Cancer Institute
How Preemptive CIML NK Cell Therapy worksNCT061385871 min

What the film says

Read the transcript

This trial is for acute myeloid leukemia and related blood cancers that are at high risk of returning after a stem cell transplant.

The idea: a week after the transplant, give extra help against leftover disease. Natural killer cells from a related donor are exposed to signaling proteins called cytokines in the lab, which makes them memory-like. They are infused with five injections of interleukin-2.

The first question is safety and the best dose. At Dana-Farber in Boston, Roman Shapiro leads this early study.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06138587

    AML and related blood cancers at high risk of returning after transplant; A week after transplant; leftover disease; NK cells from a related donor, cytokine-induced, memory-like; Five injections of interleukin-2 (+2 more lines)

The drug

What is being tested.

Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.

This is a phase I/Ib study of the pre-emptive treatment using related donor-derived cytokine induced memory-like (CIML) natural killer (NK) cells combined with Interleukin-2 (IL-2) for participants with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MDS/MPN) overlap syndrome at high risk for post-allogeneic stem cell transplant (SCT) relapse. The U.S.

The study

How the trial runs.

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant.

Names of the study therapies involved in this study are: * CIML NK cells intravenous infusion (cellular therapy) * Subcutaneous Interleukin-2 (recombinant, human glycoprotein)

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically or cytologically confirmed diagnosis of AML, MDS, or MDS/MPN that is at high risk for post-transplant relapse and that has measurable disease prior to transplant. Patients at high risk for post-transplant relapse include:
  • De novo AML diagnosed at or after age 60, except CBF AML
  • De novo AML in CR1 AND MRD+ by Hematologics Inc. flow cytometry pretransplant (this would be on the most recent pre-transplant bone marrow)
  • AML with 5 - > 10% blasts at the time of transplant who are judged by their treating clinician and study PI to have no benefit from additional pre-transplant chemotherapy
  • Any AML transplanted in CR2 or greater

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.